Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma.

ABSTRACT:

Background

Tumor-infiltrating lymphocyte (TIL) therapy is effective in metastatic melanoma (MM), but the need for resectable tumor tissue limits its accessibility. Antigen-presenting scaffolds (Ag-scaffolds) constitute a technology developed for the specific expansion of tumor-associated antigen (TAA)-specific T cells directly from peripheral blood. Ag-scaffolds are built on a dextran backbone with coattached interleukin 2 (IL-2), interleukin 21 (IL-21), and major histocompatibility complex class I molecules loaded with the top 30 most frequently expressed TAAs in MM patients. The resulting multiple antigen-specific endogenously derived T-cell (MASE-T) infusion product is enriched for CD8+ TAA-specific T cells. We hypothesize that treatment with MASE-T therapy is safe and feasible

SUBMITTER: Monberg TJ 

PROVIDER: S-EPMC12819024 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature